While we observed only mild synergy when combining ATR and ALK inhibition, we rationalised that combination with lorlatinib, which has previously been shown to reduce tumour growth in ALK-driven NB mouse models, may improve treatment responses46,49. Here, ALK is linked to neoplasm.